Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- UH Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- UHHS-Chagrin Highlands Medical Center — Beachwood, Ohio
- Cleveland Clinic Mercy Hospital — Canton, Ohio
- Aultman Health Foundation — Canton, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tum…
Sponsor: NRG Oncology
NCT ID: NCT04134260
Sites in Ohio: - Cleveland Clinic Akron General — Akron, Ohio
- Miami Valley Hospital South — Centerville, Ohio
- University of Cincinnati Cancer Center-UC Medical Center — Cincinnati, Ohio
- Cleveland Clinic Cancer Center/Fairview Hospital — Cleveland, Ohio
- Cleveland Clinic Foundation — Cleveland, Ohio
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Ohio: - Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- ProMedica Flower Hospital — Sylvania, Ohio
Phase 3 Recruiting Industry
The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.
Sponsor: AstraZeneca
NCT ID: NCT06120491
Sites in Ohio: - Research Site — Cincinnati, Ohio
- Research Site — Cincinnati, Ohio
- Research Site — Cleveland, Ohio
- Research Site — Cleveland, Ohio
- Research Site — Cleveland, Ohio
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Ohio: - University Hospitals Seidman Cancer Center at UH Avon Health Center — Avon, Ohio
- TriState Urologic Services PSC Inc. dba The Urology Group — Cincinnati, Ohio
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- University Hospitals Seidman Cancer Center at UH Mentor Health Center — Mentor, Ohio
- UH Minoff Health Center at Chagrin Highlands — Orange, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in combination with best supportive care (BSC) as compared to placebo with…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
- University Hospital of Cleveland — Cleveland, Ohio
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in Ohio: - Cleveland Clinic — Cleveland, Ohio
- Dayton Physicians Network / Greater Dayton Cancer Center — Kettering, Ohio
Phase 3 Recruiting Industry
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).
Sponsor: Amgen
NCT ID: NCT06691984
Sites in Ohio: - Cleveland Clinic Foundation — Cleveland, Ohio
- The Ohio State University — Columbus, Ohio
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
NCT ID: NCT06520345
Sites in Ohio: - University Hospital — Cleveland, Ohio
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Ohio: - Indu and Raj Soin Medical Center — Beavercreek, Ohio
- Strecker Cancer Center-Belpre — Belpre, Ohio
- Saint Elizabeth Boardman Hospital — Boardman, Ohio
- Dayton Physicians LLC-Miami Valley South — Centerville, Ohio
- Miami Valley Hospital South — Centerville, Ohio
Phase 2 Recruiting Network
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing co…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05806515
Sites in Ohio: - Good Samaritan Hospital - Cincinnati — Cincinnati, Ohio
- Bethesda North Hospital — Cincinnati, Ohio
- TriHealth Cancer Institute-Westside — Cincinnati, Ohio
- TriHealth Cancer Institute-Anderson — Cincinnati, Ohio
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Ohio: - The Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio
Phase 2 Recruiting Industry
A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Sponsor: Dendreon
NCT ID: NCT06134232
Sites in Ohio: - The Urology Group — Cincinnati, Ohio
- Central Ohio Urology Group — Gahanna, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Ohio: - Research Site 138 — Canton, Ohio
- Research Site 113 — Cincinnati, Ohio
- Research Site 131 — Dayton, Ohio
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Ohio: - University Hospitals Cleveland Medical Center, Seidman Cancer Center — Cleveland, Ohio
- Cleveland Clinic — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio
Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC …
Sponsor: Kyntra Bio
NCT ID: NCT06842498
Sites in Ohio: - University Hospitals Cleveland Medical Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Ohio: - Stefanie Spielman Comprehensive Breast Center — Columbus, Ohio
Phase 2 Recruiting Industry
This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administration of In-111-rosopatamab tetraxetan to c…
Sponsor: Convergent Therapeutics
NCT ID: NCT06549465
Sites in Ohio: - The Cleveland Clinic Foundation — Cleveland, Ohio
Phase 2 Recruiting Academic/Other
Phase 2 open-label, single-arm clinical trial evaluating the efficacy and safety of neoadjuvant olaparib + LHRH agonist administered for 6 months prior to radical prostatectomy (RP) in men with unfavorable intermediate-risk or high-risk lo…
Sponsor: Rana McKay, MD
NCT ID: NCT05498272
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called met…
Sponsor: Case Comprehensive Cancer Center
NCT ID: NCT06150417
Sites in Ohio: - University Hospitals Cleveland Medical Center Seidman Cancer Center — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiatio…
Sponsor: Angela Y. Jia, MD PhD
NCT ID: NCT06574880
Sites in Ohio: - University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Ohio: - Exelixis Clinical Site #10 — Cleveland, Ohio
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Ohio: - University of Cincinnati — Cincinnati, Ohio
- Zangmeister Cancer Center — Columbus, Ohio
- The University of Toledo — Toledo, Ohio
Phase 1 Recruiting Industry
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…
Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Ohio: - University of Cincinnati Medical Center — Cincinnati, Ohio